Later in 2023, Pfizer said late last week, its interchangeable biosimilar known as Abrilada (adalimumab-afzb) will be available at a second list price of 60% below the Humira list price. By contrast, Boehringer Ingelheim, which is the only other company with an interchangeable Humira biosimilar on the market so far, confirmed that its lowest-cost version of its interchangeable known as Cyltezo launched on Oct. 2 with an 81% discount. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER